Multiple Sclerosis Resource Centre

Welcome to the Multiple Sclerosis Resource Centre. This website is intended for international healthcare professionals with an interest in Multiple Sclerosis. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Interview with Dr. Mark Freedman: Insights on Interferon-beta 1a and 1b trials and the ORATORIO phase III trial

FREEDMAN-HD (1)

Dr. Freedman discussed some highlights from his work on interferon-beta that was presented at ACTRIMS Forum 2016. Interferon-beta are important therapeutic options for MS, and are some of the oldest treatment options for MS patients. Dr. Freedman described some of the trials of interferon-beta 1a and interferon-beta 1b that provide insight into patients with progressive MS. Long-term safety data suggests that these drugs are still useful

Dr. Freedman also described efficacy data from the ORATORIO phase III trial of ocrelizumab in patients with primary progressive MS. This is the first treatment option that has shown benefit in this group of patients. The patients most likely to benefit from this agent were those patients showing evidence of ongoing inflammation.

Dr. Mark S. Freedman, Professor of Medicine (Neurology) at the University of Ottawa, Ottawa, Ontario, Canada.

This interview was recorded at ACTRIMS 2016, February 18-20, 2016, New Orleans, USA.